Among patients with atrial fibrillation, 4-year outcomes of PRAGUE-17 randomized trial showed that left atrial appendage closure was noninferior to non-warfarin oral anticoagulation for preventing net ischemic and bleeding events.

Left Atrial Appendage Closure versus Non-Warfarin Oral Anticoagulation in Atrial Fibrillation: 4-Year Outcomes of PRAGUE-17 – Journal of the American College of Cardiology (link to abstract – $ for full-text)

Commentaries:

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term – TCTMD

PRAGUE-17: LAAC Noninferior to NOACs For Major AFib-Related CV, Neurological Events Longer-Term – American College of Cardiology

Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-Risk Atrial Fibrillation Patients – PRAGUE-17 – American College of Cardiology

Commentary on Twitter

? The PRAGUE-17 trial showed that left atrial appendage occlusion was noninferior to a #NOAC at preventing net ischemic & bleeding events. Check out ACC’s Visual Abstract from #TCT2021 to learn more here: https://t.co/NTVc4wpH6W pic.twitter.com/9EBWRvs72O

— American College of Cardiology (@ACCinTouch) November 6, 2021